Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
The aim of this study is to analyze the prognostic value of androgen receptor (AR) expression for patients with triple-negative breast cancer (TNBC). Clinical data of these patients were collected and analyzed, and immunohistochemical staining for AR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from January 1995 to December 2008. AR expression was found in 25.8% of the cases with TNBC. TNBC patients with AR negative have a higher proportion of positive lymph node. A significant correlation was found between AR expression and disease-free survival (DFS) and overall survival (OS). Univariated analysis indicated that AR expression had a significant prognostic value in TNBC patients, whereas multivariate analysis indicated that AR was a significant independent prognostic factor of DFS (P = 0.032) in all patients. Our results suggested that AR was a favorable prognostic factor of DFS and OS in patients with TNBC. Therefore, TNBC may be further divided into two subtypes according to AR status.
State Key Laboratory of Oncology in South China, 510060 Guangzhou, People's Republic of China.
Jiehua
J
He
Roujun
R
Peng
Zhongyu
Z
Yuan
Shusen
S
Wang
Jiewen
J
Peng
Guinan
G
Lin
Xiaomei
X
Jiang
Tao
T
Qin
D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011944:Receptors, Androgen / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012189:Retrospective Studies; D015996:Survival Rate; D046888:Tissue Array Analysis
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C410798:AR protein, human
J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9
9731736
Cancer. 2007 May 1;109(9):1721-8
17387718
Breast Cancer Res. 2008;10(1):R20
18307763
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
17671126
Clin Cancer Res. 2009 Apr 1;15(7):2472-8
19276248
Cancer. 2008 Nov 15;113(10):2638-45
18833576
Med Sci Monit. 2000 Mar-Apr;6(2):433-8
11208351
Am J Clin Pathol. 2003 Nov;120(5):725-31
14608899
Oncogene. 2006 Jun 29;25(28):3994-4008
16491124
Nat Med. 1998 Jul;4(7):844-7
9662379
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
17438091
Ann Oncol. 2008 Sep;19(9):1561-5
18534964
Clin Cancer Res. 2008 Dec 15;14(24):8010-8
19088017
J Steroid Biochem Mol Biol. 2002 Feb;80(2):175-89
11897502
BMC Cancer. 2007 Jul 24;7:134
17650314